Stock Watch: Bridgebio’s Endpoint A Bridge Too Far

Switch From Surrogate To Clinical Endpoint Between Phase II and III Had Big Risks

 
• By Andy Smith
  
Generate a summary of this article
Listen to this article
Beta

The news desert over the holidays meant that any Phase III clinical study announcement would be closely examined. Unfortunately, BridgeBio’s shock Phase III failure was made worse by elusive explanations.

Stock Watch Image, Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

The announcement of the results of the 12-month Part A component of BridgeBio Pharma, Inc.’s ATTRibute-CM study of acoramidis (formerly AG10), in 632 symptomatic transthyretin amyloid cardiomyopathy (ATTR-CM) patients, was supposed to provide a mandate for regulatory submissions. This was because the primary endpoint in the Phase III ATTRibute-CM study was a hard clinical measure – the six-minute walk distance (6MWD). This contrasted with the trial on which Biogen, Inc., gained a much contested and mostly un-reimbursed accelerated approval on the basis of a surrogate marker of disease.

The mean observed decline in 6MWD after 12 months was just over 9 meters for patients treated with acoramidis. This...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Stock Watch

Article Without An Author Listed

Here is a short description.

Scrip-Business (Free-1): Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 
• By Nabil

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

Stock Watch: When Development Goes Too Far

 
• By Andy Smith

R&D managers can sometimes drive a drug’s development despite evidence of its unviability. This has recently resulted in a scramble to adjust in-progress trial protocol and post-approval cost-effectiveness concerns.

Stock Watch: Bad Deals Backfire On Bayer And CSL

 
• By Andy Smith

As the pharma earnings season wrapped up, it seemed like a contest to see which company's stock price dropped the most after their announcement and which made the poorest acquisition.

More from Business

How A New Healthcare Dialogue Is Driving Market Access In Mexico

Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.